Orthocell to up stake in ‘groundbreaking’ pearl bone substitute

Orthocell has signed a Memorandum of Understanding to secure exclusive distribution rights for Marine Biomedical’s innovative bone substitute PearlBone and increase its stake in the company to 12 percent.